Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sertraline
Drug ID BADD_D02010
Description Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
Indications and Usage Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]
Marketing Status approved
ATC Code N06AB06
DrugBank ID DB01104
KEGG ID D02360
MeSH ID D020280
PubChem ID 68617
TTD Drug ID D0K0TC
NDC Product Code 76282-214; 23155-759; 68180-353; 55700-225; 63187-055; 70518-0153; 70518-1461; 70518-1617; 71335-9714; 0615-7990; 65427-009; 55154-3570; 0615-7991; 76282-212; 0904-6924; 50090-5848; 70518-1040; 23155-757; 70518-2512; 0904-6925; 68180-351; 68180-352; 68071-4400; 63187-212; 68788-7329; 0615-7989; 0904-6926; 55154-3569; 63187-478; 67296-1199; 70934-958; 76282-213; 23155-758; 50090-0989
UNII QUC7NX6WMB
Synonyms Sertraline | Zoloft | Altruline | Lustral | Apo-Sertraline | Apo Sertraline | Aremis | Besitran | Sealdin | Gladem | Novo-Sertraline | Novo Sertraline | ratio-Sertraline | ratio Sertraline | Rhoxal-sertraline | Rhoxal sertraline | Sertraline Hydrochloride | Hydrochloride, Sertraline | Sertraline Hydrochloride (1S-cis)-Isomer | Gen-Sertraline | Gen Sertraline
Chemical Information
Molecular Formula C17H17Cl2N
CAS Registry Number 79617-96-2
SMILES CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Meconium aspiration syndrome22.11.01.007; 18.04.10.0020.000013%Not Available
Infantile apnoea18.04.15.003; 22.11.02.0040.000159%Not Available
Selective eating disorder19.09.01.012; 14.03.02.0240.000070%Not Available
Allergic colitis10.01.01.009; 07.08.01.0120.000019%Not Available
Anal fissure haemorrhage24.07.02.061; 07.12.03.0100.000013%Not Available
Anaplastic large cell lymphoma T- and null-cell types stage IV16.17.02.004; 01.11.02.0040.000019%Not Available
Anembryonic gestation18.01.03.0070.000025%Not Available
Anisocoria17.02.11.009; 06.05.03.0130.000032%Not Available
Anxiety disorder due to a general medical condition19.06.01.0030.000025%Not Available
Attention deficit hyperactivity disorder19.21.04.0040.000111%Not Available
Behaviour disorder19.01.01.0050.000075%Not Available
Brief psychotic disorder with marked stressors19.03.05.0030.000038%Not Available
Brief resolved unexplained event22.11.02.012; 18.04.15.006; 17.02.05.0660.000032%Not Available
Cardiomyopathy alcoholic02.04.01.0150.000013%Not Available
Central vision loss17.17.01.027; 06.02.10.0080.000038%Not Available
Drug use disorder19.07.06.0120.000073%Not Available
Dysdiadochokinesis17.02.02.0180.000013%Not Available
Electric shock sensation17.02.07.024; 08.06.02.0230.000047%Not Available
Enteric neuropathy17.05.01.027; 14.07.07.001; 07.02.02.018; 05.07.07.0010.000019%Not Available
Facial discomfort08.01.08.0310.000025%Not Available
Fixed eruption10.01.01.037; 23.03.05.008; 08.01.06.0250.000025%Not Available
Foetal vascular malperfusion24.01.05.014; 18.05.02.0080.000089%Not Available
Gait inability17.02.05.069; 08.01.02.0110.000130%Not Available
Genital anaesthesia21.10.05.021; 17.02.06.0420.000019%Not Available
Glucose tolerance impaired in pregnancy18.02.04.005; 14.06.02.005; 05.06.02.0050.000013%Not Available
Granulocytopenia neonatal18.04.03.006; 01.02.03.0150.000013%Not Available
Hanging08.04.01.0160.000032%Not Available
Heavy menstrual bleeding21.01.03.0050.000227%Not Available
Hemiparaesthesia17.02.06.0450.000013%Not Available
Hepatic cytolysis09.01.07.0360.000083%Not Available
The 34th Page    First    Pre   34 35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene